MLNT Target Hit - Can It Carry On IN The trend?Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.
SHORT INTEREST
1.05M 08/30/19
P/E Current
-0.18
P/E Ratio (with extraordinary items)
-0.27
Average Recommendation: HOLD
Average Target Price: 12.00
MLNT
MLNT - Bullish Buying - Could Bounce The DropMelinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.
SHORT INTEREST
894.4K 08/15/19
P/E Current
-0.13
P/E Ratio (with extraordinary items)
-0.20
Average Recommendation: HOLD
Average Target Price: 12.00
$MLNT entry point for a rally$MLNT is extremely oversold and due for a rally. Huge sort position, MM's trying to drive it lower and found support. Rally is expected at any moment from this area.
Melinta Therapeutics - MNLT Continued BreakoutPossible Continuation into March 12th earnings.
*Expected quarterly revenues up 320%.
*Short interest has decreased 50.2% since mid December.
*Average daily volume is up 19% over the past 4 days.
*NDA filing for Baxdela Phase 3 data 1H 2019
Entry Points: 1.32-1.45
Price Targets: 1.74---2.00---2.26---2.43
Tight Stop-Loss at 1.25
Company Info
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.
